Literature DB >> 2178584

The captopril test in the detection of renovascular disease in hypertensive patients.

C T Postma1, P H van der Steen, W H Hoefnagels, T de Boo, T Thien.   

Abstract

A number of reports share the conclusion that the captopril test is an adequate screening procedure for the detection of renovascular disease among hypertensive patients. Therefore, we prospectively studied the value of this test in 149 consecutive hypertensive patients. The test was considered positive if plasma renin activity, after an oral dose of 25 mg of captopril, rose by more then 4.44 ng.L-1.s-1 (16.0 ng/mL per hour). The sensitivity of the test was 39%, the specificity was 96%, the positive predictive value was 81%, and the negative predictive value was 79%. No clinically important cutoff point identifying patients with renal artery stenosis could be detected in the values of baseline and stimulated plasma renin activity nor in baseline blood pressure or changes after captopril testing. The low sensitivity makes the captopril test unfit to be used as a screening procedure in an unselected hypertensive population.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2178584

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  4 in total

Review 1.  An update on renovascular hypertension.

Authors:  Martin Senitko; Andrew Z Fenves
Journal:  Curr Cardiol Rep       Date:  2005-11       Impact factor: 2.931

2.  Radiological predictors of response to renovascular reconstructive surgery.

Authors:  M D Lamawansa; R Bell; A Kumar; A K House
Journal:  Ann R Coll Surg Engl       Date:  1995-09       Impact factor: 1.891

Review 3.  The diagnosis of renovascular hypertension: the role of captopril renal scintigraphy and related issues.

Authors:  A Prigent
Journal:  Eur J Nucl Med       Date:  1993-07

Review 4.  Blockade of the renin-angiotensin system in hypertensive patients with atherosclerotic renal artery stenosis.

Authors:  Faical Jarraya; Menno Pruijm; Gregoire Wuerzner; Michel Burnier
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.